AVROBIO, Inc. to Present at Chardan’s 3rd Annual Genetic Medicines Conference

 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 3, 2019-- AVROBIO, Inc. (NASDAQ:AVRO), a Phase 2 clinical-stage gene therapy company, today announced that Geoff MacKay, President and CEO of AVROBIO, will present at Chardan’s 3rd Annual Genetic Medicines Conference on Monday, October 7, 2019.

 Chardan's 3rd Annual Genetic Medicines Conference 
Date: Monday, October 7, 2019 
Time: 3:45 p.m. ET 
Location: The Westin Grand Central Hotel, New York, NY 

A live webcast of the presentation will be available on the investors section of the AVROBIO company website at www.avrobio.com. After the live webcast, the event will remain archived on the AVROBIO website for 90 days.

 About AVROBIO, Inc. 

 AVROBIO, Inc. is a leading, Phase 2 gene therapy company focused on the development of its investigational gene therapy, AVR-RD-01, in Fabry disease, as well as additional gene therapy programs in other lysosomal storage disorders including Gaucher disease, cystinosis and Pompe disease. The Company’s plato™ platform includes a proprietary vector system, automated cell manufacturing solution and refined conditioning regimen deploying therapeutic drug monitoring. AVROBIO is headquartered in Cambridge, MA and has offices in Toronto, ON. For additional information, visit www.avrobio.com.

Source: AVROBIO, Inc.

 Investor Contact:
Christopher F. Brinzey
Westwicke, an ICR Company

 Media Contact:
Tom Donovan
Ten Bridge Communications

Investors & Media Sign up for
Email Alerts

We’ll keep you connected to the latest news about AVROBIO’s research and pipeline.